BioCentury | Mar 2, 2016
Financial News

Savara tops off $20M series C round

...offices. In 4Q16, Savara expects to start a 250-patient Phase III trial of AeroVanc ( SAV005...
...company anticipates data in 2018. He said Savara plans to seek additional funding this year. AeroVanc...
BioCentury | Mar 2, 2015
Clinical News

AeroVanc: Phase II data

...observed in patients receiving 64 mg AeroVanc. Patients received 32 and 64 mg twice-daily inhaled AeroVanc...
...to discuss the protocol for a Phase IIb or III trial of 32 mg AeroVanc. AeroVanc...
...designation in the U.S. for the indication. Savara Pharmaceuticals , Austin, Texas Product: AeroVanc ( SAV005...
BioCentury | Oct 13, 2014
Clinical News

AeroVanc: Completed Phase II enrollment

...Phase II trial evaluating 32 and 64 mg inhaled AeroVanc twice daily for 28 days. AeroVanc...
...the indication (see BioCentury, Dec. 16, 2013). Savara Inc. , Austin, Texas Product: AeroVanc ( SAV005...
BioCentury | Dec 16, 2013
Clinical News

AeroVanc regulatory update

...Savara said FDA granted Qualified Infectious Disease Product (QIDP) designation for AeroVanc to treat persistent methicillin-resistant...
...Innovation Act signed into law last year. Savara Inc. , Austin, Texas Product: AeroVanc ( SAV005...
BioCentury | Oct 28, 2013
Company News

Savara, Cystic Fibrosis Foundation infectious, drug delivery news

...Fibrosis Foundation Therapeutics Inc. (CFFT), the drug development affiliate of the not-for-profit foundation, to develop AeroVanc...
...Phase II trial to treat methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis (CF) patients. AeroVanc...
BioCentury | Apr 29, 2013
Clinical News

AeroVanc: Phase II started

...began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily 32 and 64 mg AeroVanc...
...use TOBI tobramycin inhalation solution. A DMC will evaluate the safety of the 32 mg AeroVanc...
...AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets TOBI. Savara Inc. , Austin, Texas Product: AeroVanc ( SAV005...
BioCentury | Nov 19, 2012
Clinical News

AeroVanc regulatory update

...Savara said FDA granted Orphan Drug designation for AeroVanc to treat methicillin-resistant Staphylococcus aureus (MRSA) infection...
...a Phase IIa trial of the product. Savara Inc. , Austin, Texas Product: AeroVanc ( SAV005...
BioCentury | Jun 18, 2012
Clinical News

AeroVanc: Phase Ib data

...an open-label, Australian Phase Ia/Ib trial showed that single doses of 32 and 80 mg AeroVanc...
...of the trial (see BioCentury, May 14). Savara Inc. , Austin, Texas Product: AeroVanc ( SAV005...
BioCentury | May 14, 2012
Clinical News

AeroVanc: Phase Ia data

...vancomycin-controlled, Australian Phase Ia/Ib trial showed that single doses of 16, 32 and 80 mg AeroVanc...
...well tolerated with only infrequent mild adverse events that resolved spontaneously reported. Additionally, Savara said AeroVanc...
...6 CF patients are expected this half. Savara Inc. , Austin, Texas Product: AeroVanc ( SAV005...
Items per page:
1 - 9 of 9